.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF01_Nivolumab.Nivolumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF01_Nivolumab.Nivolumab| name: | Nivolumab |
| ATC code: | L01FF01 | route: | intravenous |
| n-compartments | 2 |
Nivolumab is a fully human IgG4 monoclonal antibody that inhibits the programmed death-1 (PD-1) immune checkpoint pathway. It is approved for the treatment of various cancers, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, and others. Nivolumab enhances anti-tumor immune responses by blocking PD-1 receptor from binding to its ligands, PD-L1 and PD-L2.
Pharmacokinetic parameters were obtained from studies in adult patients with cancer, both male and female, across different tumor types. Data primarily reflect intravenous administration in clinical trial populations.
Albiges, L, et al., & George, S (2025). Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology 36(1) 99–107. DOI:10.1016/j.annonc.2024.09.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39288844
Osawa, M, et al., & Hruska, MW (2019). Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers. Cancer chemotherapy and pharmacology 83(4) 705–715. DOI:10.1007/s00280-019-03771-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/30666395
Wang, W, et al., & Yang, G (2024). Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38(6) 855–865. DOI:10.1007/s40259-024-00679-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/39317850